Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tomaralimab
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Bioasis
Deal Size : Undisclosed
Deal Type : Collaboration
Bioasis and Neuramedy Enter into Research Collaboration and License Agreement
Details : Under the terms of the agreement, Neuramedy has obtained worldwide rights to research, develop and commercialize an xB3TM version of its antibody, Tomaralimab, directed at the Toll-like receptor 2.
Brand Name : NM-101
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 10, 2022
Lead Product(s) : Tomaralimab
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Bioasis
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?